Viswanathan C T
US FDA, Division of Scientific Investigations, Office of Compliance, Center for Drug Evaluation and Research, Rockville, MD 20857, USA.
Bioanalysis. 2010 Jul;2(7):1325-9. doi: 10.4155/bio.10.85.
The concept of measuring analytes in biological media is a long-established area of the quantitative sciences that is employed in many sectors. While academic research and R&D units of private firms have been in the forefront of developing complex methodologies, it is the regulatory environment that has brought the focus and rigor to the quality control of the quantitative determination of drug concentration in biological samples. In this article, the author examines the regulatory findings discovered during the course of several years of auditing bioanalytical work. The outcomes of these findings underscore the importance of quality method validation to ensure the reliability of the data generated. The failure to ensure the reliability of these data can lead to potential risks in the health management of millions of people in the USA.
在生物介质中测量分析物的概念是定量科学中一个历史悠久的领域,在许多行业都有应用。虽然学术研究机构和私营公司的研发部门一直处于开发复杂方法的前沿,但正是监管环境为生物样品中药物浓度定量测定的质量控制带来了重点和严格要求。在本文中,作者审视了在数年生物分析工作审计过程中发现的监管问题。这些问题的结果强调了高质量方法验证对于确保所生成数据可靠性的重要性。未能确保这些数据的可靠性可能会给美国数百万人的健康管理带来潜在风险。